PCRonline @ ESC Congress 2023: the interventional cardiology perspective!

Condensed take-home messages from ESC Congress 2023

Reviews and interviews

Aaysha Cader, Ali Nazmi Calik, Alex Sticchi, Daniele Giacoppo, Dejan Milasinovic, Elad Asher, Luigi Biasco, Luis Ortega-Paz, Mirvat Alasnag, Nicola Ryan, Panos Xaplanteris, Salvatore Brugaletta and Vijay Kunadian provided their take on a selection of major Hotline Sessions, Guidelines and Late-Breaking Trials of interest to Interventional Cardiologists during ESC Congress 2023, with exclusive interviews of principal investigators!

• Timing of intervention in patients with severe tricuspid regurgitation - Interview with Julien Dreyfus
• TEER versus mitral surgery: data from a nationwide analysis - Interview with Pierre Deharo
• BIOFLOW DAPT: Biodegradable polymer SES versus durable polymer ZES in HBR subjects with 1-month DAPT
• The GUIDE-DES Trial: QCA versus IVUS guidance for DES implantation
• SHARE trial: P2Y12 Inhibitor Monotherapy vs DAPT After PCI
• FIRE trial: Physiology-Guided Complete PCI in Older MI Patient - Interview with Simone Biscaglia & Gianluca Campo
• ECLS-SHOCK: venoarterial membrane oxygenation in cardiogenic shock
• STOPDAPT-3: An Aspirin-Free antithrombotic strategy for percutaneous coronary intervention - Interview with Masahiro Natsuaki
• ILUMIEN IV: OCT Versus Angiography
• OCT-guided or angiography-guided PCI in complex bifurcation lesions: The OCTOBER trial
• OCTIVUS: OCT- vs. IVUS-Guided PCI - Interview with Duk-Woo Park & Do-Yoon Kang
• OCT vs. IVUS vs. angiography guidance: a real-time updated network meta-analysis - Interview with Gregg Stone
• 5-year results from the COMPARE-ABSORB trial - Interview with Pieter C Smits
• Three-year results of HOST-POLYTECH-ACS RCT comparing durable- vs. degradable-polymer DES
• Sex Differences in FFR- or IVUS-Guided PCI in the randomized FLAVOUR trial
• MULTISTARS AMI: Multivessel immediate versus staged revascularization in STEMI - Interview with Barbara Elisabeth Stahli
• Extended clopidogrel monotherapy versus DAPT in high-risk patients: The OPT-BIRISK trial
• ARREST trial: Expedited transfer to a cardiac arrest center for OHCA
• NOTION: The Nordic Aortic Valve Intervention Trial - Interview with Troels Hojsgaard Jorgensen
• RIVER: Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation
• 2023 ESC Guidelines for the management of Endocarditis - Interview with Victoria Delgado
• 2023 ESC Guidelines for the management of Acute Coronary Syndromes